CRL vs LGN · rev $2.00B vs rev $2.55B
Charles River Laboratories (CRL) versus Legence Corp. Class A Common stock (LGN) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Legence Corp. Class A Common stock (LGN) is a engineering & construction company listed on NASDAQ.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported LGN revenue for 2025-12-31 was $2.55B. Net income was -$59.8M. Revenue was up 21.5% from 2024-12-31 to 2025-12-31. LGN currently screens at market cap $14.66B.
CRL currently screens at market cap $7.78B. LGN currently screens at market cap $14.66B.
Not investment advice. Open the CRL and LGN stock pages for the full models.
Not investment advice.